Significantly lower methylation was recorded in the G0-tumor free control samples (14.4%; n = 7) as well as wildtype tumor samples (22.8%; n = 78) compared to EGFR/KRAS mutant samples (28.6%; n= 39) (p = 0.050 and p = 0.046; respectively) (Figure 1A). Here, KRAS is linked to neoplasm.